Open Access Correction

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

Erika Hamilton1, Kimberly Blackwell1, Amy C Hobeika2, Timothy M Clay3, Gloria Broadwater4, Xiu-Rong Ren5, Wei Chen5, Henry Castro3, Frederic Lehmann3, Neil Spector1, Junping Wei6, Takuya Osada6, H Kim Lyerly2 and Michael A Morse1*

Author Affiliations

1 Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA

2 Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA

3 GlaxoSmithKline Biologicals, Rixensart, Belgium

4 Cancer Statistical Center, Duke Cancer Institute, Durham, NC, USA

5 Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA

6 Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, NC, USA

For all author emails, please log on.

Journal of Translational Medicine 2013, 11:82  doi:10.1186/1479-5876-11-82

Published: 27 March 2013

First paragraph (this article has no abstract)

In our original manuscript [1], the corresponding author, Michael A Morse, was missed from the authors’ list. Therefore the correct author list should be: